Chiusura precedente | 62,14 |
Aperto | 64,96 |
Denaro | 0,00 x 1000 |
Lettera | 0,00 x 1000 |
Min-Max giorno | 64,47 - 66,84 |
Intervallo di 52 settimane | 46,10 - 72,72 |
Volume | |
Media Volume | 891.819 |
Capitalizzazione | 6,939B |
Beta (5 anni mensile) | 1,83 |
Rapporto PE (ttm) | 12,78 |
EPS (ttm) | 5,20 |
Prossima data utili | 24 apr 2023 - 28 apr 2023 |
Rendimento e dividendo (forward) | 0,60 (0,96%) |
Data ex dividendo | 16 dic 2022 |
Stima target 1A | 69,43 |
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
Boyd Gaming Corp. (BYD) stock has won recently despite a bumpy ride, gaining 5.5% in the last three months.
Establishes 2021 First Quarter Dividend of $0.69 per Common ShareWYOMISSING, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI” or the “Company”) today announced financial results for the fourth quarter and year-ended December 31, 2021. Financial Highlights Three Months Ended December 31,Year Ended December 31,(in millions, except per share data) 2021 Actual 2020 Actual 2021 Actual 2020 ActualTotal Revenue $298.3 $300.2 $1,216.4 $1,153.2 Income From